Envisagenics’ Post

In September, Dr. Jinjiang Guo, Head of Data Science at the Global Health Drug Discovery Institute (GHDDI), participated in the 16th Pujiang Innovation Forum - Global Health and Development Summit as a panelist. He shared his insights on current challenges and the role of new technologies in advancing global health. Looking ahead, Dr. Guo envisions the development of AI models that seamlessly integrate dynamic, multimodal, multilevel, and multiscale high-quality data. Such models would enable a deep understanding of disease progression mechanisms and provide valuable insights to scientists, enhancing the efficiency of drug discovery efforts. GHDDI leverages technologies such as AI, physics simulation, and bioinformatics analysis to identify pathogenic targets, and identify and optimize effective compounds. This accelerates the drug development process and reduces R&D costs. We are committed to improving global health through the accelerated development of new drugs and innovative technologies! Learn more about us: ghddi.org/en #AI #drugdiscovery #globalhealth #GreatScienceForGlobalHealth

It's always a pleasure to be back at TINS: Technology Innovation Studio, Unison's second home, with Suman Lal, Salma B., and the TINS team in #KendalSquare, #Cambridge, "the most innovative square mile on the planet". The Festival of #Genomics and #Biodata last week was excellent. Great to reconnect with Simeón Baker from Genomics England, Matt Newman and the team from DNAnexus, and to make many new contacts at the Broad Institute of MIT and Harvard, Massachusetts Institute of Technology, Harvard Medical School, Memorial Sloan Kettering Cancer Center, Takeda and Johnson & Johnson, not to mention the time with Shwen Gwee, as always! Next Thursday, June 27th, I'm hosting a networking, talk and collaborative brainstorming session on the Value Potential of Integrative #Multiomic Analysis in #BioPharma R&D at TINS: Technology Innovation Studio, CIC (Cambridge Innovation Center). We'll cover: 🧬 The theory behind #multiomic analysis and its value potential in drug development. 🌐 The current landscape, including challenges such as data fragmentation and accessibility. 🤖 The potential role of #FoundationModels and #AI / #machinelearning. 🔮 Envisioning of a future integrative analysis state. 🚀 The necessary technological advancements to achieve the future state. 🔗 How we can bridge critical gaps to achieve this vision. If any of the above are of interest to you, and you're in #Boston or #Cambridge, it would be great to see you there.

Daniel Leventhal, MS, PhD, Head of Immunogenicity, will present on new machine learning approaches to predict and mitigate immunogenicity risk at the Cambridge Healthtech Institute Bioassay and Immunogenicity Summit on October 4.     Dan will speak broadly about the kinds of predictive and generative models that are used in protein design. He will also demonstrate how these techniques can be applied to co-optimize amongst multiple critical drug quality attributes (like immunogenicity and developability) early in the discovery process. Learn more:     https://lnkd.in/e-uedXaN    #ProteinEngineering I #MachineLearning

Thank you Prof. Vannajan Sanghiran Lee from Moldesign for the recent visit and fruitful discussion at AGTC Genomics. MolDesign is revolutionizing the landscape of genome research, drug discovery, and development with its cutting-edge molecular design and simulation platform. 🧬💊 Their platform, which integrates advanced drug design, quantum calculations, and AI, is not just an impressive technological feat but a game-changer in how we approach molecular science. 🌐 The ability to predict molecular behavior under various conditions using their molecular simulation capabilities is opening new avenues for innovation and precision. 🧪 This meeting marks the beginning of a potential collaboration that could bridge the gap between genome research and practical drug discovery, leveraging MolDesign's platform to accelerate the journey from concept to reality. 🤝 Stay tuned as we explore these synergies and work towards advancing the frontiers of science and healthcare. #Collaboration #Innovation #DrugDiscovery #GenomeResearch #MolDesign #ScienceTech #AI Let’s innovate for a healthier tomorrow! 💡🌍

Showcasing ground-breaking data-driven solutions! From advanced analytics to cool visualisations, it's amazing to see the impact of data science in action. Everyday we come to work to explore the endless possibilities, all to create a life-changing impact! 👾#AI #innovation #Denmark #lifesciences #computing #quantumcomputing

An impactful proof-of-concept preprint! The Baker & Watson Labs at the Institute for Protein Design, University of Washington fine-tune the generative AI tool, RFdiffusion, to create truly new single-domain antibodies. We think this is a big step toward designing complex, de novo antibodies that could revolutionize drug development

AI most valuable to validate my hypothesis in 'Cracking Nature's Code' on how epigenetic actin networks are the missing masterpiece of the puzzle to the new science paradigm of 'Life as Information' has monumental potential for (R)evolutionary solutions.

During the "AI Empowering Drug Discovery, Innovation Leading Future Healthcare" seminar organized by Yunnan Baiyao Group Co., Ltd, Weijie Sun, Founder and CEO of DP Technology, participated in the event and discussed the latest advancements and future prospects of AI-driven drug discovery. Weijie Sun introduced the "AI for Science" platform, which uses advanced AI technologies to learn physical principles and enhance the efficiency and precision of drug R&D. The platform excels in quickly analyzing molecular structures, conducting dynamic studies, and optimizing molecules through sophisticated screening techniques. It is particularly effective in addressing challenging targets like membrane proteins and transcription factors through enhanced dynamic simulations. #AIinHealthcare #DrugDiscovery #DigitalHealth #HealthcareInnovation #FutureOfMedicine #QimingPortfolio #QimingHealthcare

AlphaFold 3 Unlocks Secrets of Life’s Molecules - Revolutionary Molecular Modeling: AlphaFold 3 by Google DeepMind can predict structures and interactions of biomolecules like proteins, DNA, and RNA, enhancing drug discovery and treatment development. - Advanced AI Techniques: Features improved deep learning architectures, such as the Evoformer module and a diffusion network, boosting prediction accuracy for complex molecular interactions. - Accessible AI Technology: AlphaFold Server launched, providing free access for researchers to use AlphaFold 3 for non-commercial research, democratizing advanced molecular prediction technology. Subscribe to our daily newsletter here for more AI news https://lnkd.in/g8YaPTtq #Technology #Innovation #AI #ArtificialIntelligence #Healthcare #Research #Biotechnology #DataScience #Engineering #Science

Discover AI's impact on drug discovery with GPU-powered BioNeMo at #GTC24. On Mar 20, at 10am CET, learn how NVIDIA and Innophore innovate protein design, analyze biomolecular data, and apply insights through case studies in therapeutic breakthroughs.